Valuation: Bonesupport Holding AB

Market Cap 13.77B 1.4B 1.22B 1.15B 1.04B 1.96B 134B 1.96B 5.31B 68.09B 5.24B 5.13B 219B P/E 2026 *
42.9x
P/E 2027 * 27.3x
Enterprise Value 13.22B 1.34B 1.17B 1.1B 1B 1.88B 129B 1.89B 5.1B 65.4B 5.04B 4.92B 210B EV / Sales 2026 *
8.86x
EV / Sales 2027 * 6.54x
Free-Float
89.54%
Yield 2026 *
0.69%
Yield 2027 * 1.02%
1 day+25.07%
1 week+22.14%
Current month+20.87%
1 month+18.07%
3 months+27.45%
6 months+49.12%
Current year+43.02%
1 week 207
Extreme 207
268.4
1 month 203.8
Extreme 203.8
268.4
Current year 167.55
Extreme 167.55
272.5
1 year 167.55
Extreme 167.55
309.6
3 years 111.8
Extreme 111.8
404.4
5 years 34.65
Extreme 34.65
404.4
10 years 12.06
Extreme 12.06
404.4
Manager TitleAgeSince
Chief Executive Officer 49 01/09/2025
Director of Finance/CFO 63 01/11/2018
Chief Operating Officer 51 01/12/2021
Director TitleAgeSince
Director/Board Member 68 01/01/2010
Chairman 70 15/12/2016
Chairman 71 14/05/2019
Change 5-day change 1-year change 3-year change Capi.($)
+25.07%+22.14% - - 1.4B
-0.58%+0.43%+32.58%-6.20% 78.37B
-2.55%+6.99%+510.30%+44.31% 61.5B
-1.11%+5.08%-11.48%-33.39% 59.78B
+0.14%-1.20%-11.21%+24.73% 46.53B
-0.24%+1.22%+2.36%+154.40% 45.5B
-1.62%-0.76%+51.23%-16.04% 31.84B
-1.81%+3.16%+44.82%+106.78% 25.4B
+0.47%+3.26%+4.94%+144.25% 21.43B
+0.27%+1.96%+59.19%+106.18% 15.77B
Average +1.80%+2.20%+75.86%+58.34% 42.9B
Weighted average by Cap. -0.83%+2.35%+94.90%+39.85%

Financials

2026 *2027 *
Net sales 1.49B 151M 132M 125M 113M 212M 14.51B 213M 576M 7.38B 568M 556M 23.74B 1.97B 200M 174M 165M 150M 280M 19.19B 281M 761M 9.76B 751M 735M 31.4B
Net income 318M 32.28M 28.15M 26.58M 24.14M 45.23M 3.1B 45.41M 123M 1.58B 121M 119M 5.07B 503M 51M 44.47M 41.99M 38.13M 71.44M 4.89B 71.74M 194M 2.49B 192M 187M 8.01B
Net Debt -543M -55.04M -48M -45.32M -41.15M -77.1M -5.28B -77.43M -209M -2.69B -207M -202M -8.64B -855M -86.72M -75.62M -71.41M -64.84M -121M -8.32B -122M -330M -4.23B -326M -319M -13.61B
Logo Bonesupport Holding AB
Bonesupport Holding AB is a Sweden-based orthobiologics company. It develops and commercialize injectable bioceramic bone graft substitutes which remodel to host bone and have the capability to elute drugs directly into the bone void. The marketed synthetic bone graft substitutes are CERAMENT BVF, CERAMENT G and CERAMENT V, which are based on the CERAMENT technology platform. The products are commercially available in Europe and the United States, as well as in India, Malaysia, Oman and Singapore. The products are developed to treat patients with fractures and bone voids caused by trauma and related surgery, as well as caused by infection or diseases, such as chronic osteomyelitis, revision arthroplasty and infected diabetic foot.
Employees
171
Date Price Change Volume
18/09/26 SEK 208.47 -6.18% 58,147
17/09/26 SEK 222.19 +1.29% 39,692
16/09/26 SEK 219.37 +0.34% 5,994
15/09/26 SEK 218.63 -0.84% 48,644
14/09/26 SEK 220.49 +0.34% 9,610
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
210.20SEK
Average target price
356.58SEK
Spread / Average Target
+69.64%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!